{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:30:32Z","timestamp":1787974232692,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001308","name":"Jean Shanks Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1746-1","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T08:20:21Z","timestamp":1540887621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5095-4150","authenticated-orcid":false,"given":"Matthew","family":"Roughley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyshah Abdul","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Clarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Whittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D.","family":"Mallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"1746_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74:661\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1746_CR2","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136\u201341.","journal-title":"Arthritis Rheum"},{"key":"1746_CR3","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson D, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11:e0158765.","journal-title":"PLoS One"},{"key":"1746_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0002-9343(82)90593-9","volume":"72","author":"TF Yu","year":"1982","unstructured":"Yu TF, Berger L. Impaired renal function gout: its association with hypertensive vascular disease and intrinsic renal disease. Am J Med. 1982;72:95\u2013100.","journal-title":"Am J Med"},{"key":"1746_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/0002-9343(75)90222-3","volume":"59","author":"L Berger","year":"1975","unstructured":"Berger L, Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605\u201313.","journal-title":"Am J Med"},{"key":"1746_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0002-9343(79)90076-7","volume":"67","author":"WJ Fessel","year":"1979","unstructured":"Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74\u201382.","journal-title":"Am J Med"},{"key":"1746_CR7","first-page":"2073","volume":"12","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","unstructured":"Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;12:2073\u201381.","journal-title":"Lancet"},{"key":"1746_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659\u201363.","journal-title":"Arch Intern Med"},{"key":"1746_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:1\u201312.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1746_CR10","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1186\/ar3272","volume":"13","author":"Luc\u00eda Cea Soriano","year":"2011","unstructured":"Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2010;13:R39.","journal-title":"Arthritis Research & Therapy"},{"key":"1746_CR11","doi-asserted-by":"publisher","first-page":"e006843","DOI":"10.1136\/bmjopen-2014-006843","volume":"5","author":"W Wang","year":"2015","unstructured":"Wang W, Bhole VM, Krishnan E. Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart Study. BMJ Open. 2015;5:e006843.","journal-title":"BMJ Open"},{"key":"1746_CR12","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1002\/art.38171","volume":"65","author":"E Krishnan","year":"2013","unstructured":"Krishnan E. Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study. Arthritis Rheum. 2013;65:3271\u20138.","journal-title":"Arthritis Rheum"},{"key":"1746_CR13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.165.7.742","volume":"165","author":"HK Choi","year":"2005","unstructured":"Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The Health Professionals Follow-up Study. Arch Intern Med. 2005;165:742\u20138.","journal-title":"Arch Intern Med"},{"key":"1746_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","volume":"40","author":"E Roddy","year":"2014","unstructured":"Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin N Am. 2014;40:155\u201375.","journal-title":"Rheum Dis Clin N Am"},{"key":"1746_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/kisup.2013.79","volume":"3","author":"R Kazancioglu","year":"2013","unstructured":"Kazancioglu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 2013;3:368\u201371.","journal-title":"Kidney Int Suppl"},{"key":"1746_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"C Hsu","year":"2009","unstructured":"Hsu C, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease - 25-year follow-up. Arch Intern Med. 2009;169:342\u201350.","journal-title":"Arch Intern Med"},{"key":"1746_CR17","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar3806","volume":"14","author":"KH Yu","year":"2012","unstructured":"Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14:R83.","journal-title":"Arthritis Res Ther"},{"key":"1746_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1746_CR19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society For Rheumatology guideline for the management of gout. Rheumatology. 2017;56:e1\u2013e20.","journal-title":"Rheumatology"},{"key":"1746_CR20","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431\u201346.","journal-title":"Arthritis Care Res"},{"key":"1746_CR21","doi-asserted-by":"publisher","first-page":"e0187550","DOI":"10.1371\/journal.pone.0187550","volume":"12","author":"X Su","year":"2017","unstructured":"Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis. PLoS One. 2017;12:e0187550.","journal-title":"PLoS One"},{"key":"1746_CR22","unstructured":"Clinical Practice Research Database. Available at: \n                    https:\/\/www.cprd.com\/\n                    \n                  . Accessed 25 Oct 2018."},{"key":"1746_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Staa T, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44:827\u201336.","journal-title":"Int J Epidemiol"},{"key":"1746_CR24","volume-title":"HES for physicians: a guide to the use of information derived from Hospital Episode Statistics","author":"Royal College of Physicians & UHCE","year":"2007","unstructured":"Royal College of Physicians & UHCE. HES for physicians: a guide to the use of information derived from Hospital Episode Statistics. London: Royal College of Physicians & UHCE; 2007."},{"key":"1746_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"CF Kuo","year":"2016","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75:210\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1746_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2125.1997.00647.x","volume":"44","author":"CR Meier","year":"1997","unstructured":"Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol. 1997;44:175\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1746_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"1746_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","volume":"4","author":"U Dafni","year":"2011","unstructured":"Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4:363\u201371.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1746_CR29","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31:2963\u20139.","journal-title":"J Clin Oncol"},{"key":"1746_CR30","first-page":"2145","volume":"54","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis. Rheumatology. 2015;54:2145\u201350.","journal-title":"Rheumatology"},{"key":"1746_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13075-017-1322-0","volume":"19","author":"A Abdul Sultan","year":"2017","unstructured":"Abdul Sultan A, Mallen C, Hayward R, Muller S, Whittle R, Hotston M, et al. Gout and subsequent erectile dysfunction: a population-based cohort study from England. Arthritis Res Ther. 2017;19:123.","journal-title":"Arthritis Res Ther"},{"key":"1746_CR32","doi-asserted-by":"publisher","first-page":"e100831","DOI":"10.1371\/journal.pone.0100831","volume":"9","author":"P Jain","year":"2014","unstructured":"Jain P, Calvert M, Cockwell P, McManus RJ. The need for improved identification and accurate classification of stages 3-5 chronic kidney disease in primary care: retrospective cohort study. PLoS One. 2014;9:e100831.","journal-title":"PLoS One"},{"key":"1746_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123.","journal-title":"BMC Med"},{"key":"1746_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"RJ Johnson","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71:851\u201365.","journal-title":"Am J Kidney Dis"},{"key":"1746_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/annrheumdis-2015-209046","volume":"76","author":"JA Singh","year":"2017","unstructured":"Singh JA, Yu S. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure. Ann Rheum Dis. 2017;76:133\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1746_CR36","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3899\/jrheum.131159","volume":"41","author":"GD Levy","year":"2014","unstructured":"Levy GD, Rashid N, Niu F, Cheetham TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol. 2014;41:955\u201362.","journal-title":"J Rheumatol"},{"key":"1746_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2296-14-170","volume":"14","author":"E Cottrell","year":"2013","unstructured":"Cottrell E, Crabtree V, Edwards JJ, Roddy E. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract. 2013;14:170.","journal-title":"BMC Fam Pract"},{"key":"1746_CR38","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66:1311\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1746_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12891-017-1465-9","volume":"18","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18:108.","journal-title":"BMC Musculoskelet Disord"},{"key":"1746_CR40","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2741\/3950","volume":"17","author":"M Jin","year":"2012","unstructured":"Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci. 2012;17:656\u201369.","journal-title":"Front Biosci"},{"key":"1746_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/art.1780340203","volume":"34","author":"E Pascual","year":"1991","unstructured":"Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991;34:141\u20135.","journal-title":"Arthritis Rheum"},{"key":"1746_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jbspin.2012.09.017","volume":"80","author":"E Roddy","year":"2013","unstructured":"Roddy E, Menon A, Hall A, Datta P, Packham J. Polyarticular sonographic assessment of gout: a hospital-based cross-sectional study. Joint Bone Spine. 2013;80:295\u2013300.","journal-title":"Joint Bone Spine"},{"key":"1746_CR43","first-page":"39","volume":"4","author":"SR Kingsbury","year":"2011","unstructured":"Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39\u201349.","journal-title":"J Inflamm Res"},{"key":"1746_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1590\/S0101-28002011000300012","volume":"33","author":"HR Vianna","year":"2011","unstructured":"Vianna HR, Soares CM, Tavares MS, Teixeira MM, Silva AC. Inflammation in chronic kidney disease: the role of cytokines. J Bras Nefrol. 2011;33:351\u201364.","journal-title":"J Bras Nefrol"},{"key":"1746_CR45","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2010020143","volume":"21","author":"A Vilaysane","year":"2010","unstructured":"Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21:1732\u201344.","journal-title":"J Am Soc Nephrol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1746-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T17:14:01Z","timestamp":1572455641000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1746-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1746-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"20 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the CPRD in-house Independent Scientific Advisory Committee (ISAC) reference number 15_214RA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have completed the Unified Competing Interest form at  (available on request from the corresponding author) and declare that: the authors do not have any support from any company for the submitted work; the authors do not have any relationships with any companies that might have an interest in the submitted work in the previous 3\u00a0years; their spouses, partners, or children do not have any financial relationships that may be relevant to the submitted work; and the authors do not have any non-financial interests that may be relevant to the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"243"}}